Medscape4d
Ensitrelvir Shows Promise for COVID-19 Prevention Following Exposure
The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...
C&EN8d
Pfizer readies its next-generation COVID-19 antiviral
An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...
pharmaphorum2d
Enanta lawsuit claims Pfizer's Paxlovid infringes its patent
However, it "seeks fair compensation for Pfizer's use of a coronavirus 3CL protease inhibitor claimed in the '953 patent." There's a potential third wheel in the dispute, according to SVB ...
Nasdaq15d
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
targeting the Mpro (3CL protease), without the need for co-administration of ritonavir. Some of the statements in this release are forward-looking statements within the meaning of Section 27A of ...
Business Insider18d
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
targeting the Mpro (3CL protease), without the need for co-administration of ritonavir. Traws is committed to delivering novel compounds for unmet medical needs using state-of-the-art drug development ...
manilatimes15d
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
targeting the Mpro (3CL protease), without the need for co-administration of ritonavir. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the ...
Nasdaq15d
Traws Pharma, Inc. Reports Positive Topline Results from Ferret Studies on Tivoxavir Marboxil for H5N1 Bird Flu Treatment
targeting the Mpro (3CL protease), without the need for co-administration of ritonavir. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the ...
pharmaphorum1d
Six months after authorization, what do we know about Paxlovid?
How does the drug work? The active drug is nirmatrelvir, a protease inhibitor, which helps keep the SARS-CoV-2 protein from replicating. SARS-CoV-2-3CL protease is an enzyme COVID-19 needs to ...
Business Wire6d
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post-Exposure Prophylaxis (SCORPIO-PEP) assessing ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622 ...